Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.

Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
• Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
• Children's Place (PLCE) Misses Q2 EPS by 20c